Lei Wu

Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate <scp>T</scp> cells by inducing degradation of <scp>T</scp> cell repressors <scp>I</scp> karos and <scp>A</scp> iolos via modulation of the <scp>E</scp> 3 ubiquitin ligase complex <scp>CRL</scp> 4 <scp> ^CRBN </scp>

Anita K. Gandhi, Jian Kang, Courtney G. Havens et al. · British Journal of Haematology · 2013 · 621 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

Lei Wu, Mary Adams, Troy Carter et al. · Clinical Cancer Research · 2008 · 434 citations · Full text

Life Sciences, Immunology, Pharmacology +17

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

Ling Lu, Faribourz Payvandi, Lei Wu et al. · Microvascular Research · 2008 · 224 citations

Medicine, Oncology, Pharmacology +17

Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function

Anita K. Gandhi, Jingfen Kang, Lori Capone et al. · Current Cancer Drug Targets · 2010 · 168 citations

Life Sciences, Pharmacology, Pharmacotherapy +17

Chemical genomics reveals histone deacetylases are required for core regulatory transcription

Berkley E. Gryder, Lei Wu, Girma M. Woldemichael et al. · Nature Communications · 2019 · 153 citations · Full text

Life Sciences, Molecular Biology, Oncology +17